Literature DB >> 20442656

Primary antibody deficiency syndromes.

Philip M Wood1.   

Abstract

PURPOSE OF REVIEW: The primary antibody deficiency syndromes are a rare group of disorders presenting at any age, with complex polygenic disorders, most commonly the common variable immunodeficiency disorders (CVIDs), predominating. With increasing patient survival on immunoglobulin therapy, there is an increasing focus on the complications of these disorders. Research into the cause of CVIDs has made use of the increased understanding of immune regulatory systems and B-cell signalling events and has made significant progress in the past 12 months. RECENT
FINDINGS: Prevalence data from different geographical regions have been supplemented by more detailed incidence data on primary antibody deficiencies, revealing trends in diagnosis and management. Continued exploration of the role of genetic variations in TACI in CVID populations has improved our understanding of possible pathogenic events. The key role of naturally occurring regulatory T cells in the development of immune dysregulation in CVIDs has become more apparent. The role of dysfunction of the innate immune system in pathogenesis of CVID has begun to emerge. Novel clinical presentations of these disorders continue to be described.
SUMMARY: The recent findings in these areas will allow more precise prognostic and diagnostic information to be available for individual patients. The challenge remains to separate primary disease-causing factors from secondary disease-modifying phenomena.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442656     DOI: 10.1097/MOH.0b013e328338f69e

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  12 in total

Review 1.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

Review 2.  Targeting BAFF in autoimmunity.

Authors:  Anne Davidson
Journal:  Curr Opin Immunol       Date:  2010-10-21       Impact factor: 7.486

Review 3.  Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 4.  Novel sequencing-based strategies for high-throughput discovery of genetic mutations underlying inherited antibody deficiency disorders.

Authors:  Hong-Ying Wang; Ashish Jain
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 5.  Therapeutic management of primary immunodeficiency in older patients.

Authors:  Nisha Verma; Anthony Thaventhiran; Benjamin Gathmann; James Thaventhiran; Bodo Grimbacher
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

6.  Therapeutic Antibodies: An Overview.

Authors:  Gunnar Houen
Journal:  Methods Mol Biol       Date:  2022

7.  Impaired release of antimicrobial peptides into nasal fluid of hyper-IgE and CVID patients.

Authors:  Andreas Cederlund; Marie Olliver; Rokeya Sultana Rekha; Monica Lindh; Lennart Lindbom; Staffan Normark; Birgitta Henriques-Normark; Jan Andersson; Birgitta Agerberth; Peter Bergman
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

8.  Fertility, pregnancies and outcomes reported by females with common variable immune deficiency and hypogammaglobulinemia: results from an internet-based survey.

Authors:  Adi V Gundlapalli; Christopher Scalchunes; Marcia Boyle; Harry R Hill
Journal:  J Clin Immunol       Date:  2015-01-09       Impact factor: 8.317

9.  Hypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.

Authors:  Francisco Martinez-Torres; Tomonori Nochi; Angela Wahl; J Victor Garcia; Paul W Denton
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

10.  Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?

Authors:  Marian-Christopher Pott; Natalie Frede; Jennifer Wanders; Lennart Hammarström; Erik-Oliver Glocker; Cristina Glocker; Fariba Tahami; Bodo Grimbacher
Journal:  BMC Immunol       Date:  2017-06-26       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.